Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors

  Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors

Business Wire

NEWTOWN, Pa. -- July 29, 2013

Onconova Therapeutics, Inc. (NASDAQ: ONTX)today announced the appointment of
Dr. Jerome Groopman and Anne VanLent to the Board of Directors.

“I am pleased to welcome Dr. Groopman and Ms. VanLent to Onconova,” commented
Ramesh Kumar, Ph.D., President and Chief Executive Officer of Onconova.
“Jerry’s medical and regulatory expertise in hematology/oncology combined with
his familiarity with our programs, having previously chaired Onconova’s
Clinical Advisory Board, will be valuable as we approach important data
readouts. Anne brings deep experience from serving on the boards of
publicly-traded life science companies and will provide oversight as the Chair
of our audit committee. Our board looks forward to working with them.”

Dr. Groopman has served as the Dina and Raphael Recanati Professor of Medicine
at Harvard Medical School since January 1992. He has also served as Attending
Hematologist/Oncologist at Beth Israel Deaconess Medical Center since July
1996. Dr.Groopman received a M.D. from Columbia University College of
Physicians and Surgeons, and a B.A. in Political Philosophy from Columbia
College.

Ms.VanLent has served as President of AMV Advisors, a personal consulting
firm providing strategic and financial services to companies in the greater
life sciences sector, since May 2008. Ms.VanLent has also served as a
director and chair of the audit committee of Biota Pharmaceuticals,Inc. since
May 2013, Aegerion Pharmaceuticals,Inc. since April 2013 and Ocera
Therapeutics,Inc. since March 2011. From December 2004 to May 2013,
Ms.VanLent was a director of Integra Life Sciences Holding Corporation,
serving as a member of the audit committee from December 2004 to May 2013 and
as its chair from May 2006 to May 2012, as well as serving as a member of the
compensation committee from 2005 to 2006. From 1998 to 2010, Ms.VanLent
served as a director of Penwest PharmaceuticalsCo., where she was chair of
the audit committee between 1999 and 2010 as well as chair of the nomination
and governance committee from 2008 to 2010. Ms.VanLent received a B.A. degree
in Physics from Mount Holyoke College.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on
discovering and developing novel products to treat cancer. Onconova's clinical
and pre-clinical stage drug development candidates are derived from its
extensive chemical library and are designed to work against specific cellular
pathways that are important in cancer cells, while causing minimal damage to
normal cells. In addition to rigosertib, the Company’s most advanced product
candidate, two other candidates are in clinical trials, and several candidates
are in pre-clinical stages. For more information, please visit
http://www.onconova.com.

Contact:

Onconova Therapeutics
Benjamin Hoffman, 267-759-3680
bhoffman@onconova.us
or
Media:
MacDougall Biomedical Communications
Doug MacDougall, 781-235-3060
dmacdougall@macbiocom.com